Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    Lenvatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 43,714Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Akeso Starts Global Cadonilimab Trial in Resistant Liver Cancer
    Akeso Starts Global Cadonilimab Trial in Resistant Liver Cancer

    15 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/akeso-announces-first-patient-dose-in-global-registrational-trial-of-cadonilimab-pd-1ctla-4-for-pd-1-treatment-resistant-hepatocellular-carcinoma-302555984.html

    PR NEWSWIRE
    15 Sep 2025
    Share Share
    ImmuneOncia Reveals Phase 1b Results for CD47 Antibody at ASCO
    ImmuneOncia Reveals Phase 1b Results for CD47 Antibody at ASCO

    02 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immuneoncia-announces-interim-results-from-phase-1b-clinical-trial-of-next-generation-cd47-antibody-imc-002-at-asco-2025-302470514.html

    PR NEWSWIRE
    02 Jun 2025
    Share Share
    Merck, Eisai combo misses survival goal in GI cancer trial
    Merck, Eisai combo misses survival goal in GI cancer trial

    25 Jan 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/merck-eisai-star-crossed-keytruda-lenvima-combo-misses-survival-goal-gi-cancer-trial

    FIERCE PHARMA
    25 Jan 2025
    Share Share
    KEYTRUDA Plus LENVIMA With TACE Improves PFS In Liver Cancer
    KEYTRUDA Plus LENVIMA With TACE Improves PFS In Liver Cancer

    14 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240914167509/en

    BUSINESSWIRE
    14 Sep 2024
    Share Share
    Medivir To Present Fostrox + Lenvima Data At ESMO And Host Webcast
    Medivir To Present Fostrox + Lenvima Data At ESMO And Host Webcast

    12 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/medivir-to-present-mature-clinical-data-for-fostrox--lenvima-at-esmo-conference-and-to-host-a-webcast-on-september-16-302246468.html

    PR NEWSWIRE
    12 Sep 2024
    Share Share
    Eisai To Present E7386 At ESMO Annual Meeting
    Eisai To Present E7386 At ESMO Annual Meeting

    08 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eisai-to-present-e7386-co-created-by-prism-biolab-and-eisai-at-the-esmo-european-society-for-medical-oncology-annual-meeting-302241213.html

    PR NEWSWIRE
    08 Sep 2024
    Share Share